Biopharma Deal Strategy Outlook
Exploring the current challenges and potential opportunities expected to shape the biopharma deal landscape.
The industry continues to face headwinds and so far 2024 has been slightly slower than 2023 and the prior two years. Factors such as higher interest rates, the loss of patent exclusivity, political uncertainty, potential policy changes, and other dynamic market conditions are impacting deal-making and the pace of innovation. However, amidst these challenges, there are also emerging market trends and advancements in therapeutic approaches that present exciting opportunities.
As we approach 2025, this paper offers valuable insights into the trends, challenges, and opportunities that will shape the industry.
Dive into our thinking:
Explore more
Insight
Biopharma deal trends outlook for 2023: Q3’22 M&A trends in lifesciences
Near-term headwinds, with possible run on small biotechs on the horizon
Insight
Inflation Reduction Act impact on biopharma portfolio strategies
An examination of potential implications for how drug manufacturers manage their portfolios in the wake of the Inflation Reduction Act
Insight
Our thinking: A new era of precision medicine
A new era of precision medicine: The unprecedented impact of generative AI across the precision medicine landscape
Subscribe to KPMG Healthcare and Life Sciences Insights
Industry insights and trends, one click away.
Meet our team
